Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

106.13 +1.57 (+1.50%)
Official Closing Price Updated: 7:00 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
65 66 Next >
Weight Loss Drug's Ozempic Counterfeit: Rising Reports Over Patient Safety Related Fake Drugs
Discover the alarming rise in fake Ozempic cases, leading to hypoglycemia. Learn about FDA investigations, counterfeit warnings, and the surge in reports. 
Via Benzinga
Exposures Product Safety
Investors seeking growth at a reasonable cost should explore NYSE:NVO.
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is showing decent growth, but is still valued reasonably. 
Via Chartmill
Jim Cramer Says Eli Lilly Could Replace Tesla In 'Magnificent Seven' List: 'To Ignore...Is To Reject The Facts'
Jim Cramer has hinted at the possibility of Tesla being replaced by Eli Lilly in the "Magnificent Seven" list of mega-cap stocks. 
Via Benzinga
3 Phenomenal Stock-Split Stocks You Should Be Buying Now
Because the market sees stock splits as a sign of future growth these stock-split stocks could be tomorrow's winners. 
Via InvestorPlace
European Drug Regulator To Consider Expanded Use Of Novo Nordisk's Wegovy Weight-Loss Drug
EMA's discussions on extending Novo Nordisk's Wegovy for reducing stroke and heart attack risks. SELECT trial results support its integration into public health systems. 
Via Benzinga
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
Is Novo Nordisk Stock a Buy Now?
The biotech is on a roll, and that won't end soon. 
Via The Motley Fool
Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money
Healthcare is nearly a fifth of America's economy. Ride these high-flying healthcare stocks to monster gains. 
Via The Motley Fool
Topics Economy
Exposures Economy
3 High-Flying Stocks That Could Soar Even More in 2024
These big winners could keep the momentum going. 
Via The Motley Fool
Weightloss Drugs Ozempic And Wegovy's Success Sets Novo Nordisk's Owner To Utilize Dividend Windfall For Strategic Investments
Explore Novo Holdings' 2024 plans for acquisitions and investments in Asia, led by CEO Kasim Kutay. Discover strategic initiatives, global studies on NVO drugs, and insights into challenges and... 
Via Benzinga
Check Out What Whales Are Doing With NVO
Via Benzinga
2 biotechs with promising weight-loss drugs coming
Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co. 
Via MarketBeat
Why Novo Nordisk Stock Soared 53% in 2023 (Hint: It Wasn't Just Ozempic)
Last year was one for the history books for the Danish drugmaker. 
Via The Motley Fool
$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,600 Today
Via Benzinga
P/E Ratio Insights for Novo Nordisk
Via Benzinga
These 2 Top Healthcare Stocks Declared Dividend Raises in 2023
For different reasons, both Eli Lilly and UnitedHealth are doing well enough to enact substantial dividend raises. 
Via The Motley Fool
Move Over, Novo Nordisk -- This Is the Pharmaceutical Company I am Most Bullish On in 2024
Novo Nordisk may dominate the weight management space, but pharma giant Eli Lilly is quickly gaining steam. 
Via The Motley Fool
After Surging 53% in 2023, This Pharmaceutical Stock Might Be About to Crash. Here's Why I'm Probably Wrong
The rise of Ozempic and Wegovy helped Novo Nordisk stock surge over 50% last year. 
Via The Motley Fool
3 Unstoppable Stocks to Buy in 2024
These stocks appear to be on a clear path to continued growth. 
Via The Motley Fool
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looks to Supercharge Reach, Impact of GLP-1 Agonists with Proprietary Drug-Delivery Solution
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Looking At Novo Nordisk's Recent Unusual Options Activity
Via Benzinga
Why WW International Stock Plummeted by 9% Today
The beleaguered company suffers another share price hit with a somewhat gloomy analyst update. 
Via The Motley Fool
FDA Finds No Evidence Weight-Loss Drugs Cause Suicidal Thoughts
The FDA released an update on Thursday stating that its preliminary review did not find definitive evidence that the drugs cause suicidal thoughts or actions. However, the FDA investigation will... 
Via Benzinga
Exposures Product Safety
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the  
Via Benzinga
Pfizer’s 2024 Outlook: Is PFE Stock Poised for a Major Rebound?
Pfizer is certainly a company that will need to continue to battle headwinds moving forward, but is PFE stock worth a buy? 
Via InvestorPlace
AstraZeneca: Rebound in 2024 with double-digit earnings growth
AstraZeneca's stock rose 8.95% in the past month on a bullish outlook, driven by growing sales of cancer and diabetes drugs and a strategic acquisition 
Via MarketBeat
Exposures COVID-19
Why Eli Lilly Stock Skyrocketed 59% in 2023
Lilly's pipeline success in 2023 allowed it to to claim the crown as the biggest drugmaker on the planet by market cap. 
Via The Motley Fool
Bullish Continuation In '24? 3 Market Areas To Watch
This article discusses 3 market areas that should outperform dramatically over the next 12 months... 
Via Talk Markets
Analyst Assesses Cell-Programming Focused Ginkgo Bioworks' Positioning Amid Revenue Surge, Program Adjustments
Wednesday, Ginkgo Bioworks Holdings Inc (NYSE: DNA) released preliminary FY23 sales of $250 million-$260 million, compared to the consensus of $258.65 million. 
Via Benzinga
Bring On The Competition In Obesity Drugs: Novo Nordisk CEO Optimistic About Prolonged Patient Adherence to Obesity Drug Wegovy
Lars Fruergaard Jorgensen, CEO of Novo Nordisk A/S (NYSE: NVO), shared insights during the JPMorgan Healthcare conference, highlighting Wegovy's efficacy for weight loss, indicating that patients are... 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.